Iain Kilty
Directeur/Membre du Conseil chez Octagon Therapeutics, Inc.
Profil
Iain joined SV Health Investors as a Venture Partner in 2022 and is the CSO for SV portfolio company Sitryx Therapeutics.
Iain has over 25 years of global biopharmaceutical industry experience leading programmes from idea through to clinical development across a range of indications and therapeutic modalities.
He developed as a drug discoverer through a 22-year tenure at Pfizer, starting as an internal industrial postdoc and taking on roles of increasing responsibility working across the drug discovery paradigm from target identification to leading the early clinical cluster in Rheumatology and Dermatology.
Ultimately Iain served as Vice President Preclinical Sciences in the Inflammation and Immunology Research Unit, where he was responsible for a portfolio of both small and large molecule programmes targeted across rheumatology, dermatology and gastroenterology.
Iain left Pfizer at the end of 2018 to join Atlas Venture where he was the Chief Scientific Officer of Quench Bio, responsible for the company’s scientific strategy and execution, whilst also working as an Entrepreneur in Residence across the Atlas portfolio.
Academic Credentials
Iain graduated with a BA and MA Cantab in Biochemistry from Jesus College, University of Cambridge, UK, before completing his Ph.D in the Breast Cancer Research Laboratories at the University of Liverpool, UK.
Postes actifs de Iain Kilty
| Sociétés | Poste | Début |
|---|---|---|
Sitryx Therapeutics Ltd.
 Sitryx Therapeutics Ltd. Medical SpecialtiesHealth Technology Sitryx Therapeutics Ltd. Focuses on regulating cell metabolism to develop disease-modifying therapeutics in immuno-oncology and immuno-inflammation. It treats cancer and inflammatory conditions by targeting the metabolism of immune cells. The company was founded by Houman Ashrafian, Paul-Peter Tak, Luke O'Neill, Jonathan Powell, Jeff Rathmell and Michael Rosenblum and is headquartered in London, the United Kingdom. | Corporate Officer/Principal | 01/04/2021 |
SV Health Investors LLP
 SV Health Investors LLP Investment ManagersFinance SV Health Investors LLP (SV Health Investors) is a venture capital firm founded in 1994 by Peter McPartland. The firm is headquartered in London. | Private Equity Investor | 01/03/2022 |
Octagon Therapeutics, Inc.
 Octagon Therapeutics, Inc. BiotechnologyHealth Technology Octagon Therapeutics, Inc. engages in the research and development of medicines based on novel metabolic targets in disease-causing bacteria, lymphocytes, and cancer cells. It develops a discovery platform that identifies novel therapeutic targets and small molecule inhibitors that are invisible in standard culture conditions. The company was founded by Fred Ausubel, Isaac Stoner, and Shen Yu in 2016 and is headquartered in Allston, MA. | Directeur/Membre du Conseil | 01/01/2020 |
Anciens postes connus de Iain Kilty
| Sociétés | Poste | Fin |
|---|---|---|
Quench Bio, Inc.
 Quench Bio, Inc. BiotechnologyHealth Technology Quench Bio, Inc. develops therapies targeting innate immune pathways to treat life-threatening auto-immune and inflammatory diseases. The company was founded by Mark J. Tebbe, Mike Nolan, and Arturo Zychlinsky and is headquartered in Cambridge, MA. | Corporate Officer/Principal | 01/04/2021 |
| PFIZER, INC. | Private Equity Investor | 01/01/2019 |
| Partners For Global Research&Development | Private Equity Investor | 01/08/2011 |
Formation de Iain Kilty
| University of Cambridge | Graduate Degree |
| University of Liverpool | Doctorate Degree |
Expériences
Fonctions occupées
Relations
Relations au 1er degré
Entreprises liées au 1er degré
Homme
Femme
Administrateurs
Exécutifs
Sociétés liées
| Sociétés cotées | 1 |
|---|---|
| PFIZER, INC. | Health Technology |
| Entreprise privées | 5 |
|---|---|
SV Health Investors LLP
SV Health Investors LLP Investment ManagersFinance SV Health Investors LLP (SV Health Investors) is a venture capital firm founded in 1994 by Peter McPartland. The firm is headquartered in London. | Finance |
Sitryx Therapeutics Ltd.
Sitryx Therapeutics Ltd. Medical SpecialtiesHealth Technology Sitryx Therapeutics Ltd. Focuses on regulating cell metabolism to develop disease-modifying therapeutics in immuno-oncology and immuno-inflammation. It treats cancer and inflammatory conditions by targeting the metabolism of immune cells. The company was founded by Houman Ashrafian, Paul-Peter Tak, Luke O'Neill, Jonathan Powell, Jeff Rathmell and Michael Rosenblum and is headquartered in London, the United Kingdom. | Health Technology |
Octagon Therapeutics, Inc.
Octagon Therapeutics, Inc. BiotechnologyHealth Technology Octagon Therapeutics, Inc. engages in the research and development of medicines based on novel metabolic targets in disease-causing bacteria, lymphocytes, and cancer cells. It develops a discovery platform that identifies novel therapeutic targets and small molecule inhibitors that are invisible in standard culture conditions. The company was founded by Fred Ausubel, Isaac Stoner, and Shen Yu in 2016 and is headquartered in Allston, MA. | Health Technology |
Quench Bio, Inc.
Quench Bio, Inc. BiotechnologyHealth Technology Quench Bio, Inc. develops therapies targeting innate immune pathways to treat life-threatening auto-immune and inflammatory diseases. The company was founded by Mark J. Tebbe, Mike Nolan, and Arturo Zychlinsky and is headquartered in Cambridge, MA. | Health Technology |
| Partners For Global Research&Development |
